{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-094440","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2026-08-12T11:03:08+00:00","discovered_at":"2026-08-12T11:05:00.426044+00:00","generated_at":"2026-08-12T11:05:07.512750+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Humacyte Q2: Symvess sales up, net loss $36.8M; V012 Phase 3 hits primary endpoint","bullets":["Q2 2026 Symvess sales $0.4M vs $0.1M prior year; net loss $36.8M vs $37.7M.","V012 Phase 3 interim: ATEV beat AV fistula, 91 more catheter-free days (p=0.0007), infections 6 vs 23/100 pt-yrs.","Plans sBLA for dialysis access with FDA in H2 2026; FDA accepted IND for CTEV in CABG, Phase 2a expected Q3 2026.","Raised $57.5M gross in June public offering; restructuring cuts ~45 staff, saving ~$14.3M in 2026.","Cash $80.3M at 6/30/26; six-month net loss $54.4M vs net income $1.5M year ago."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-094440","json":"https://secwatch.observer/filing/0001104659-26-094440.json","markdown":"https://secwatch.observer/filing/0001104659-26-094440.md","text":"https://secwatch.observer/filing/0001104659-26-094440.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926094440/0001104659-26-094440-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926094440/tm2622949d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T11:05:07.512750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}